PROTEIN ENGINEERING MARKET ANALYSIS

Protein Engineering Market, By Product Type (Modified Enzymes, Insulin, Monoclonal Antibodies, Coagulation Factors , Vaccines , Growth Factors, and Other Product Types), By Technology (Irrational Protein Design and Rational Protein Design ), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Institutions, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024
Code : CMI5272
Pages :170
Formats :
Excel and PDF
Industry : Biotechnology

Key Developments

In January 2024, Agilent Technologies Inc., life sciences, diagnostics company introduced a novel automated parallel capillary electrophoresis system designed for protein analysis
In January 2024, Biognosys , proteomics company expanded its presence in the U.S. by establishing a new proteomics CRO facility in Massachusetts. This expansion enabled Biognosys to offer proteomics services to its biopharma clients in the U.S. Biognosys was acquired by Bruker Corporation, American manufacturer of scientific instruments for molecular and materials research in January 2023.
In December 2023, Thermo Fisher Scientific, Inc. global supplier of analytical instruments, life sciences solutions disclosed a distribution agreement with AESKU.GROUP GmbH, research-focused supplier of innovative and efficient products and services to facilitate the support, marketing, and sale of its array of U.S.FDA-cleared automated instruments, IFA products, and software across the U.S.
In April 2024, the Laboratory for Bioengineering Research and Innovation, funded by Northpond, made an investment in the Wyss Institute for the AmnioX project. This initiative aims to advance the development of protein-based drugs, thereby enhancing patients' access to medications.
In March 2023, Arzeda , industry-leading Protein Design Company partnered with Takeda, apanese multinational pharmaceutical company. to utilize artificial intelligence-based protein design technology. This collaboration seeks to optimize protein biologics more effectively, potentially improving the development process and resulting products in therapeutic protein development.